ERBB2 and breast cancer: Building on these findings, a phase II trial (NCT04329065) assessed WOKVAC in combination with neoadjuvant taxane-based chemotherapy and HER2-targeted monoclonal antibodies (e.g., trastuzumab, pertuzumab) in HER2-positive breast cancer [134].